By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merck & Co., Inc. 

One Merck Drive
P.O. Box 100
Whitehouse Station  New Jersey  08889-0100  U.S.A.
Phone: 908-423-1000 Fax: n/a


SEARCH JOBS


Company Overview

Merck and Co., Inc., Whitehouse Station, NJ USA, is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.

With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.

At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.

Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.

Embracing Partnerships

At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.

Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.

Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.

Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.

Contact Information

To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Tel: 903-423-4350; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.

For further information, please visit our website at http://www.merck.com/licensing/



YEAR FOUNDED:

1891

LEADERSHIP:

Founder: George Merck

CEO: Kenneth Frazier

CFO: Robert Davis

JOBS:

Please click here for Merck job opportunities.

CLINICAL TRIAL

Please click here for clinical trial information.


PRODUCTS:

All Products

FOLLOW MERCK:

Tweets by Merck




Key Statistics


Email:
Ownership: Public

Web Site: Merck & Co.
Employees: 70,000
Symbol: MRK
 



Industry
Big Pharma


Collaborations

Actelion Pharmaceuticals US, Inc.  Cardiovascular

Acumen Pharmaceuticals Inc.  Alzheimer's disease

AMRI  Chemistry

AMRAD Corporation Limited  Respiratory

AVEO Oncology  Cancer

Bristol-Myers Squibb  Diabetes

Cambridge Major Laboratories, Inc.  Chemistry

deCODE genetics  Obesity, Pharmacogenomics

DOV Pharmaceutical  Depression

Exelixis  High-throughput screening

Genetronics, Inc.  DNA vaccine technology

Intercell AG  Bacterial vaccines

Kalypsys, Inc.  High-throughput screening

MerLion Pharmaceuticals Pte Ltd  Natural products

MethylGene  Antibacterials

Nastech Pharmaceutical Company Inc.  Obesity

Neurogen Corporation  Pain

NicOx SA  Nitric oxide-donating compounds

Norak Biosciences, Inc.  Cell lines

Ono Pharma  Stroke

Pierre Fabre  Cancer

Rigel  Cancer

Roberts Pharmaceutical Corporation  Imaging technology

SCYNEXIS, Inc.  Antifungals

Symyx Technologies, Inc.  High-throughput screening

Taisho Pharmaceutical  Neuroscience

TransTech Pharma, Inc.  Diabetes

University of Edinburgh  Schizophrenia

WuXi PharmaTech  Chemistry

Kinexis Inc.  Sleep disorders

Kynin  Infection

University of Dundee  Kinase consortium

Arena  Cardiovascular

BioXell S.p.A.  Sepsis

Cambridge Antibody Technology (CAT)  Antibody technology and library

Celera Corporation  Genome databases, Alzheimer's disease, Diagnostics

Verenium Corporation  Therapeutic antibodies

Metabasis Therapeutics, Inc.  – Hepatitis C, Diabetes / Hyperlipidemia

Gilead 

Gilead (Seattle, WA) 

Gilead (Durham, NC) 

Vertex  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Cubist 

Gilead (Seattle, WA) 





Company News
Merck & Co. (MRK) Congratulates Guatemala As Fourth Country In Latin America To Achieve WHO Verification Of Elimination Of River Blindness 9/30/2016 9:49:35 AM
Two New Trials Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) As Monotherapy And In Combination With Chemotherapy For First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer To Be Presented During Presidential Session At ESMO 2016 9/28/2016 11:30:33 AM
Two New Trials Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) As Monotherapy And In Combination With Chemotherapy For First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer To Be Presented During Presidential Session At ESMO 2016 9/28/2016 11:25:58 AM
Merck & Co. (MRK) To Present New Research Focused On Hard-To-Treat Cancers At ESMO 2016 9/28/2016 10:53:06 AM
Merck & Co. (MRK)’s Keytruda Finds Fast Entry Into China Via Medical-Tourism Push 9/26/2016 5:58:32 AM
Merck & Co. (MRK) To Hold Third-Quarter 2016 Sales And Earnings Conference Call On October 25 9/23/2016 10:39:05 AM
Merck & Co. (MRK) To Host Investor Teleconference To Discuss ESMO 2016 Highlights 9/20/2016 11:41:42 AM
JenKem Technology And Merck & Co. (MRK) Announce Distribution Agreement 9/19/2016 8:59:50 AM
Roche (RHHBY) Says New MS Drug Works Better Than Merck & Co. (MRK)'s Rebif 9/19/2016 7:23:43 AM
Sanofi (SNY) Files U.S. Suit Against Merck & Co. (MRK) Over Patents 9/19/2016 6:35:30 AM
12345678910...
//-->